The Indivior share price is smashing the FTSE 250. Should I buy now?

The Indivior share price has been leading the FTSE 250 for days, on the back of great 2020 results. I’m trying to decide whether to buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I have my eyes open for recovery stocks for 2021, and Indivior (LSE: INDV) has come storming into view. The FTSE 250 as a whole is sitting on a 6% loss over the past 12 months. But the Indivior share price has jumped by more than 250% in the same period.

It’s still way down on a 2018 peak, with the shares going into tailspin in 2019. But what’s this new lease of life all about? And are we looking at long-term sustainable growth? The surge of the past few days is down to the company’s latest update.

Indivior is a pharmaceuticals company, specialising in opioid addiction treatment. The tragic opioid addiction crisis is big, especially in the USA. Sad though that is, any improvements in 2020’s profit outlook is good news for the firm. And that’s exactly what it delivered on 15 January. I could tell it was good just by looking at the Indivior share price, which jumped nearly 10% on the day.

Indivior share price soaring

My Motley Fool colleague Manika Premsingh made a prediction: “I reckon that the latest news will provide continued impetus for INDV’s share price.” And how prescient that seems now. On Tuesday, it leads the FTSE 250 again, up another 9% at the time of writing. After a solid Monday too, the Indivior share price has now climbed 24% since the update was released.

Indivior had previously indicated full-year revenue in the range of $595m to $620m. The results have easily exceeded that, with new expectations put at $645m to $650m. The company’s Sublocade product plays a big part in that, with net revenue now expected to come in between $128m and $130m (up from guidance of $120m to $125m). Other product revenue looks to be largely in line with guidance.

On top of better-than-expected revenue, Indivior reported operating expenses slightly below guidance. Overall, the company “now expects to deliver adjusted pre-tax income ahead of its previous expectations.” Quite how far ahead we don’t yet know, so we’ll have to wait until full results are delivered on 18 February.

Should I buy now?

This all sounds good. But with the Indivior share price having more than trebled over the past year, would I buy now? Well, my portfolio might benefit from a growth stock or two. As far as future demand goes, I can’t see an end to the opioid crisis any time soon. Not when the majority of drugs-related deaths around the world are down to opioids.

But I remain cautious for several reasons. One is that Indivior’s results have been a bit erratic. And I really like to see at least a slightly longer-term positive run before I buy a stock. The other is a £1bn claim brought against the company in November, by former parent Reckitt Benckiser

Indivior reckons the claim is baseless, but I’d rather wait and see. I might be missing some top growth profits by turning away from the Indivior share price right now. But I prefer to minimise risk these days, and there are many lower-risk investment candidates out there.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Q1 results boost the Bunzl share price: investors should consider the stock for stability

As the Bunzl share price edges higher, our writer considers whether this so-called boring FTSE 100 stock looks like a…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

The top 5 investment trusts to buy in a resurgent UK stock market?

These were the five most popular investment trusts at Hargreaves Lansdown in April. And they're not the ones I'd have…

Read more »